A patient with chronic active Epstein-Barr virus (EBV) infection was treated by allogeneic SCT from an HLAidentical sibling donor, using a nonmyeloablative regimen. Even on day 70, mixed chimerism remained together with a quite high viral load. On days 76 and 90, donor lymphocytes were infused after short-term culture with OKT3 plus recombinant IL-2. At 8 days after the last dose, all hematopoietic cells were shown to be donor-type dominant; thereafter, the viral load started to decrease and finally disappeared. Anti-mHA-specific CTLs were generated in vitro, which were shown to be effective in eradicate viral-infected recipient T lymphocytes.
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Chronic active Epstein-Barr virus (CAEBV) infection is a life-threatening disorder and in most cases incurable by conventional treatment, such as antiviral drugs or anticancer drugs. Recently, successful treatment by SCT from a sibling donor has been reported by Okamura et al. 1 In contrast, as reported by Fujii et al 2 or Kimura et al, 3 several patients have died because of transplant-related toxicity, even if the EBV genome disappeared soon after transplantation.
The so-called 'mini-transplantation' using less-intensive nonmyeloablative conditioning regimens has been applied especially to complicated cases, in which the therapyrelated risk of standard 'full-transplantation' is considered to be too high. 4 Considering such poor results of previously reported 'full-transplantation' in CAEBV cases, 'minitransplantation' was chosen for our patient, although the patient was young and had no significant complications.
Case report
A 27-year-old woman was diagnosed with lymphoma, and a rectal tumor was biopsied in October 1998. The pathological finding of the biopsy was Ki-1 positive nonHodgkin's lymphoma by in situ hybridization and PCR assay. The malignant cells were shown to be EBV (LMP-1) positive, retrospectively. She was treated with intensive chemotherapy and local irradiation, and had a complete response. In March 2001, she complained of high-fever, recurrent tonsillitis and mild liver dysfunction. Although her anti-EBV antibody titers (VCA-IgG, Â 2560 and EA-DR IgG, Â 320) did not meet or fulfill the criteria (VCAIgG 4 Â 5120, EA-DR-IgG4 Â 640) of Straus 5 or Okano et al, 6 the diagnosis of CAEBV was made based on abnormally high serum and peripheral blood (PB) mononuclear cells (MNCs) copies of the EBV genome (2.6 Â 10 3 copies/ml and 3 Â 10 5 copies/mg, respectively) by PCR assay. Also, EBER-1 staining revealed that more than 50% of MNCs were positive and viruses were monoclonally integrated by Southern hybridization using an EBVterminal repeat (TR) probe. TCR-gd lymphocytes accounted for about 60% of PB-MNCs by flow cytometry, and this population was purified by sorting after a shortterm culture with recombinant IL-2 (Shionogi Pharmaceutical, Osaka, Japan) on immobilized anti-CD3 MoAb (OKT3; Janssen-Kyowa, Tokyo, Japan). This selected population was again strongly positive for EBV-copy numbers and monoclonality was shown using the TCR-Jg probe. Karyotype abnormalities were not detected for these EBV-infected T lymphocytes. In our institute, two of five CAEBV cases have already died either of severe hepatic failure or cardiac failure 1-2 years after the diagnosis. Thus, we decided to treat her by allo-transplantation from an HLA-matched, EBV-seropositive sister (32 years old). The conditioning regimen was fludarabine at 25 mg/kg intravenously daily for 5 days and cyclophosphamide at 60 mg/kg for 2 days. Cyclosporin A at 3 mg/kg was used for prophylaxis against GVHD. On Day 30 after transplantation, 40% of CD3+T lymphocytes or PB-PMNs were shown to be of donor origin by short tandem repeat (STR) assay. Thereafter, the percentage of donor-derived T cells was persistently less than 50% and that of PB-PMNs gradually decreased to less than 20%. EBV-copy numbers in PB-MNCs only slightly decreased to 6 Â 10 4 copies/mg of DNA. In most cases of CAEBV, T and/or NK lymphocytes are the major infected subsets, which are activated as they express HLA-DR antigens. 7 In our patient too, recipient gd T cells strongly expressed HLA-DR and also IFN-g after non-specific activation with PMA and ionomycin by intracellular cytokine staining (data not shown). Then, we considered those T cells were rejecting donor-hematopoietic engraftment and decided to infuse cultured activated donor T lymphocytes. We took 10 ml of peripheral blood from the donor, and MNCs were separated using Lymphoprep (AXIS-SHIELD Poc ac, Oslo, Norway). The cells were then cultured for 2 weeks with recombinant IL-2 (700 IU/ ml at the beginning and 175 IU/ml from day 3) on OKT3 MoAb (10 mg/ml). The cumulative expansion of the cultured cells was more than 100-fold, and their phenotype was as follows; CD3+ cells 91%, CD4+ cells 22%, CD8+ cells 61% and CD3-CD56+ 9%; 70% of CD3+ cells expressed IFN-g after nonspecific activation with PMA and ionomycin by intracellular cytokine staining. The final cell product was confirmed to be negative for bacteria, fungi and endotoxins. On days 76 and 90 after transplantation, 5 Â 10 7 and 5 Â 10 8 of those cultured cells were infused into the recipient, respectively, without short-term adverse reactions. At 1 week after the last dose (day 98 after the transplant), STR assay proved that both T cells and PBPMNs were donor-type dominant. EBV-copy numbers also declined and became undetectable on day 124. Finally, the frequency of TCR-gd was normalized at under 5%. Simultaneously, a decrease of white blood cell counts, especially of neutrophils (frequency of eosinophils was significantly elevated), and an increase of liver enzymes (AST, ALT, ALP) was observed together with a generalized erythematous rash. We judged those data and clinical symptoms as GVHD, which was controlled with prednisolone. On day 168, she was discharged from our hospital. Now on day 300, the viral load is zero and GVHD is well controlled with a small dose (2.5 mg/day) of prednisolone ( Figure 1) .
On day 120 after transplantation, PB-MNCs were again harvested from the recipient, and were proven to be engrafted donor lymphocytes by STR assay. They were then repeatedly (three times) stimulated with the patient's EBV-transformed lymphoblastoid cell line (EB-LCL). The expanded cells were separated into CD4-and CD8-positive cells using immunobeads, and examined for their cytotoxic activity against various targets by Treatment of SCAEBV by cultured donor T cells after allografting F Yoshiba et al but did not kill B62 negative ones as shown in Figure 3 . These patterns of cytotoxicity indicated that CD8+T cells recognized mismatched mHA, 8 whereas CD4+ T cells were considered to be anti-EBV-specific CTLs.
Discussion
This is the first report of SCT with a nonmyeloablative regimen being applied in a CAEBV case. We consider that SCT should be considered even in the early phase of the disorder, especially in adult onset cases, as there has been no other effective therapy and poor outcomes. As EBVinfected NK/T cells were resistant to the chemotherapeutical agents usually employed for the conditioning regimen of SCT, 9,10 GVH reaction may play an important role in eradicating the patient's virus-infected T cells. As expected, those infected T cells were rapidly eliminated from the patient's system following the GVH reaction, which was induced by infusion of donor-activated T lymphocytes.
The in vitro assay also clearly revealed that not anti-EBV, but anti-host mHA-specific CD8+ T cells were generated after the T cells infusion. Donor lymphocytes infusion (DLI) may be additionally required to eradicate residual malignant cells or to control host antidonor immunological rejection, especially in 'mini-transplantation' cases.
11 DLI, however, is sometimes impossible, because of difficult donation, especially in unrelated SCT. Recently, activated T-cells infusion was shown to be feasible and effective to lower postsurgical recurrence rates of hepatocellular carcinoma. 12 Umbilical cord blood T lymphocytes could also be expanded 1000-fold, which was equivalent to that of adult PB-T lymphocytes. 13 In the near future, those activated T-cell infusions from allogeneic donors should become more widely applied. Treatment of SCAEBV by cultured donor T cells after allografting F Yoshiba et al
